Addex Therapeutics (ADXN) Receivables (2018 - 2026)
Addex Therapeutics (ADXN) posted Receivables of $40853.9 for Q1 2026, up 62.56% sequentially from $25132.2 in Q4 2025, and up 3.87% YoY from $39330.3 in Q1 2025.
Addex Therapeutics (ADXN) Receivables (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Receivables for 9 years, with the latest figure at $40853.9 in Q1 2026.
- Quarterly Receivables rose 3.87% year-over-year to $40853.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40853.9 (up 3.87% YoY) and the FY2025 annual result came in at $24227.5, down 80.26% from the prior year.
- Receivables advanced to $40853.9 in Q1 2026 per ADXN's latest filing, from $25132.2 in the prior quarter.
- Over five years, Receivables peaked at $681642.1 in Q2 2024 and troughed at $25132.2 in Q4 2025.
- A 5-year average of $326360.7 and a median of $422706.1 in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2025: Receivables surged 131.61% in 2022, then slumped 89.25% in 2025.
- Over 5 years, Receivables stood at $557288.0 in 2022, then tumbled by 69.4% to $170532.7 in 2023, then declined by 27.73% to $123246.7 in 2024, then slumped by 79.61% to $25132.2 in 2025, then surged by 62.56% to $40853.9 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $40853.9, $25132.2, and $64064.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | 40,853.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,853.93 |
| Dec 31, 2025 | 25,132.25 |
| Sep 30, 2025 | 64,064.36 |
| Jun 30, 2025 | 118,992.89 |
| Mar 31, 2025 | 39,330.29 |
| Dec 31, 2024 | 123,246.69 |
| Sep 30, 2024 | 596,157.27 |
| Jun 30, 2024 | 681,642.07 |
| Mar 31, 2024 | 257,832.37 |
| Dec 31, 2023 | 170,532.66 |
| Sep 30, 2023 | 422,706.14 |
| Jun 30, 2023 | 558,625.76 |
| Mar 31, 2023 | 466,489.22 |
| Dec 31, 2022 | 557,288.01 |
| Sep 30, 2022 | 473,244.07 |
| Jun 30, 2022 | 481,371.33 |
| Mar 31, 2022 | 470,623.17 |
| Dec 31, 2021 | 319,694.95 |
| Sep 30, 2021 | 634,381.77 |
| Jun 30, 2021 | 1.35 Mn |